Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$29.86 USD
+0.33 (1.10%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $30.22 +0.37 (1.22%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 29.86 +0.33(1.10%)
Will AGIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
Other News for AGIO
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report